Gene therapy with IL -12 has been shown to elicit potent systemic antitumor response in a variety of tumors. Although direct intratumoral injection is the most commonly used delivery route for gene therapy of solid tumors, the skeletal muscle has been shown to be an ideal tissue for gene delivery to produce systemic gene expression. We have previously demonstrated that electroporation delivery of a reporter gene to muscle enhances the transfection efficiency and the level of gene expression by two to three logs. We report here that intramuscular ( i.m. ) injection of as little as 10 g of the IL -12 DNA plasmid followed by electroporation prevents squamous cell carcinoma ( SCCVII ) tumor establishment in up to 40% of experimental animals and reduces the volume of established tumors by 75% compared to controls ( P < .05 ) . By comparison, there was no difference in tumor growth observed between IL -12 injection alone and injection of empty vector with or without electroporation. The induction of antitumor activity by i.m. electroporation delivery of the IL -12 gene is associated with an increase in IL -12 expression in muscle and serum. The level of IL -12 expression in muscle and serum was 1500 pg / tibialias muscle and 170 pg / mL serum, respectively, at day 6, after the gene was delivered by electroporation. In contrast, the level of IL -12 when the gene was injected without electroporation was hardly detectable after subtracting the background level of IL -12 detected in naõ Ève mice. The high level of IL -12 expression led to a 170 -fold induction of IFN -expression in serum at day 6 after i.m. electroporation delivery of IL -12 DNA plasmid, which was equal to 1450 pg / mL in the serum. The induction of antitumor activity by i.m. electroporation delivery of the IL -12 gene also correlates with increased CD8 + T -cell population in peripheral blood but not in spleen. Our findings suggest that i.m. delivery of IL -12 gene using electroporation is an effective method of inducing a systemic antitumor response against SCC. Cancer Gene Therapy ( 2001 ) 8, 151 ± 157
I L -12, produced by antigen -presenting cells, is one of the most effective cytokines for cancer treatment. 1 ± 3 Systemic daily treatment with IL-12 recombinant protein generated a significant inhibitory effect on the growth of metastases of B16F10 melanoma and on established RENCA or CT26 tumors. 4, 5 However, recombinant IL -12 protein therapy has resulted in severe toxicity in several experimental animal studies 6 and in early -stage human trials. 7 This has prompted investigators to explore new methods of IL -12 therapy.
IL-12 gene therapy has shown less toxicity than protein therapy. 8 Gene delivery is achieved by either viral vectors or by using nonviral methods, e.g., liposomes. Nonviral gene therapy of solid tumors is commonly delivered via intratumoral injection. Although nonviral gene therapy is safer and much less expensive than viral therapy, it has relatively lower gene transfection efficiency. These limitations in gene transfection and expression reduce the therapeutic efficacy of nonviral intratumoral gene therapy particularly in cases of multiple or metastatic tumors. Skeletal muscle is an attractive tissue for somatic gene delivery because it is large, has good capacity for protein synthesis, is easily accessible for intramuscular (i.m.) injection, and can take up plasmid after i.m. administration. 9 However, one major challenge for the use of muscle as an effective route of gene therapy is to produce high levels of gene expression for an adequate period of time in order to achieve therapeutic efficacy.
Electroporation is a highly effective method for increasing gene expression by creating transient pores in the cell membrane through which the plasmid can gain entry into the cell. Electroporation delivery of gene therapy has been tested in many tissues, but the application to muscle has only been investigated over the past few years. Most of the data related to muscle electroporation delivery are based on the investigation of reporter genes, 10 except for one report in which erythropoietin was delivered to muscle using electroporation to generate a therapeutic effect. 11 To date, muscle electroporation gene delivery has not been tested in any disease model. We present data to demonstrate that electrotransfection of the IL-12 gene into muscle induced significant and durable expression of IFN -, increased
CD8
+ T-cell population in peripheral blood, and inhibition of tumor establishment and growth.
MATERIALS AND METHODS

Experimental animals
Female 6-to 8 -week -old C3H / HeJ mice weighing 18 ± 20 g were purchased from Jackson Laboratories. The mouse strain C3H /HeJ was used because this strain can host squamous cell carcinoma ( SCCVII ) and is immunocompetent, which is appropriate for testing cytokine gene therapy against SCC. Animals were maintained under NIH guidelines at 378C, 12-hour day /night cycle, and 80% relative humidity.
IL-12 expression plasmid structure and preparation for animal application An IL -12 construct was provided by Valentis ( The Woodlands, TX ). The structure of the construct, which contains both subunits of IL -12, is depicted in their publication. 12 The backbone elements of this construct are described in our previous publication. 13 The control construct is the result of deletion of IL -12 cDNA. All plasmids were manufactured using the Qiagen Giga Endo-Free Prep Kit (Valencia, CA ) and run for quality control as described previously. 13 
SCCVII tumor generation in mice and tumor growth monitoring
SCCVII is a spontaneously arising murine SCC. We obtained this cell line from Dr. Candice Johnson's laboratory at the University of Pittsburgh. The cells were maintained in AIM -V growth medium with 10% fetal bovine serum ( Gibco, Grand Island, NY ) . Mice were subcutaneously inoculated with 1Â10 5 SCCVII cells in a volume of 30 L. When the established tumor reached a measurable size (2 ± 3 mm ) , mice were randomly divided into groups of five mice each. As soon as treatment was started, tumor growth was monitored twice a week using a caliper. Tumor volume was calculated using the formula:
14 V= (Dd 2 /4 ), where V is volume, D is maximum tumor diameter, and d is diameter at 90 to D. At the completion of the study, mice were euthanized with CO 2 narcosis.
Electroporation delivery of DNA plasmid
Purified plasmids were formulated at 150 mM NaCl as described previously. 13 Animals were anesthesized by intraperitoneal ( i.p. ) administration of a mixture of ketamine (42.8 mg /mL ), xylazine ( 8.6 mg /mL ) , and acepromazine (1.4 mg /mL ) at a dose of 1.8 ±2.0 mL / kg. The tibialis muscles were injected i.m. with a 10-L formulation containing 10 g DNA using a 28.5 -gauge needle. Animals receiving plasmid delivery by electroporation had two heads of a caliper electrode positioned to two sides of the leg, with contact to the skin, following the injection of DNA. Pulses were applied to the leg through the electrode using a power supply device ( BTS ECM 830, Genetronic, CA ). The parameters were 375 V / cm, two of 20 -millisecond pulses.
Enzyme -linked immunoassay analysis ( ELISA ) of IL-12 and IFNMice were bled from the retro -orbital plexus. The blood was centrifuged at 4000 rpm for 5 minutes and serum was collected using serum separators ( Becton Dickinson, Franklin Lakes, NJ ) for IL -12 and IFN -expression analysis. Muscles were harvested from euthanized animals, snap -frozen in liquid nitrogen, and lyophilized overnight. Muscle extract supernatant was assayed for IL -12 expression and total protein concentration. IL -12 and IFN -were analyzed with ELISA (R&D Systems, Minneapolis MN ) following the manufacturer's instructions. The color changes were read by a precision microplate reader ( Molecular Devices ) .
Muscle protein extraction and assay
Lyophilized muscles were homogenized with silica beads for 2 minutes with a mini bead -beater ( Biospec Products, Bartlesville, OK ) . After adding 1 mL of luciferase cell lysis buffer ( Promega, Madison, WI ) to the powdered muscle, the samples were homogenized for another 3 minutes. The suspension was centrifuged at 14,000 rpm for 15 minutes, and the supernatant was used to assay total protein. The total protein was determined with the BCA protein assay kit ( Pierce, Rockford, IL ) described previously. 13 
Flow cytometric analysis
Spleens taken from sacrificed mice were homogenized gently in a 70 -m nylon mesh, and red blood cells were lysed with red blood cell lysis solution on ice. The fluorescein isothiocyanate (FITC ) anti -CD8 ( Ly2 ) antibody, the phycoerythrin (PE ) -labeled anti-CD4 (L3T4 ) antibody, and the FITC -labeled anti -NK antibody were all purchased from BD PharMingen (San Diego, CA ) for staining of CD4 + , CD8 + T, and NK cells, respectively. Lymphocytes were doubled -stained with anti-CD4 and -CD8 antibodies or with anti-NK antibody alone for 20 minutes in ice, washed once with PBS, and analyzed on a FACscan (Becton Dickinson, Mountain View, CA ).
Histologic analysis
To evaluate muscle damage, the entire anterior tibialis muscle was removed and placed in 10% neutral buffered formalin for 6 hours at room temperature. The tissue was processed to paraffin, and 5-m paraffin sections were cut and dried for 1 hour in a 608C oven. These were subsequently cleaned in xylene, rehydrated in PBS, and stained with hematoxylin and eosin. Following three washes in PBS, a cover slip was placed over each slide using Vectashield mounting media (Vector Laboratories, Burlingame, CA ) .
Statistical analysis
Tumor growth and expression of IL -12 or IFN -were the main outcomes measured. Experimental data were analyzed by one -way analysis of variance. Means of individual treatments were compared using the Student's t test when the result was significant. Statistical significance was defined as a P value less than .05.
RESULTS
IL-12 gene expression in muscle and serum
To test if electroporation can improve the level and duration of IL -12 expression and if muscle can secrete IL -12 into the serum, we determined the level of IL -12 gene expression over time in both serum and muscle. Blood samples were collected from five mice treated with or without electroporation delivery of IL -12 gene and naõ Ève mice on days 6, 9, and 14 after administration of plasmid. As shown in Figure 1A average serum IL-12 levels at day 6 were 170 pg /mL, with electroporation, after subtracting the background level of IL-12 (about 62 pg/ mL ) detected in naõ Ève mice. This was 8.8-fold higher than the expression observed in control mice receiving IL -12 by injection only. The level of expression reached a peak at day 9 and declined by day 14. In muscle, the average IL -12 level was 1500 pg /tibialis muscle by day 6, which was 150 -fold higher than that of controls ( Fig 1C ) . This level of increase in gene expression using muscle electroporation was within the range that we found using reporter genes.
To determine if electroporation delivery was also able to enhance the level of gene expression with repeated administration, blood was collected on day 7 after the final delivery of plasmid from mice treated once a week with four administrations of IL -12 DNA plasmid, with or without electroporation. Four different hind limb muscles were used, proceeding from the left to right tibialis and from the left to right gastrocnemius muscle. Again, the serum levels of IL -12 from the electroporated sample were higher ( 7.7 -fold ) than that of injection alone ( Fig 1D ) after subtracting the background level of IL -12 detected from naõ Ève mice. These results clearly demonstrate that electroporation delivery of the IL -12 gene enhanced the level of expression with either single or repeated administration.
IFN -gene expression in serum
To determine if the IL -12 secreted from muscle is biologically functional in vivo, we determined the level of induction of IFN -gene expression in serum after treatment with IL -12 gene therapy or control plasmid delivered with or without electroporation. Blood samples were collected on days 3, 6, 9, and 14 after administration of plasmid. As demonstrated in Figure 1B average serum IFN -levels at day 6 were 1450 pg /mL when the gene was delivered by Figure 1 . Levels of IL -12 expression and induction of IFN -in vivo following administration of IL -12 gene to hind limb tibialias muscles of tumor -bearing mice using electroporation or injection alone. Five mice were used for each treatment or control group. The dose of either IL -12 or empty vector DNA plasmid was 10 g. The level of IL -12 expression in muscle or serum, determined using ELISA, represents the net value after subtracting expression levels in mice treated with empty plasmid vector. The error bars in the figures represent the mean standard deviation ( SD ) . IJ = DNA was delivered into muscle by injection alone without electroporation; EP = DNA was delivered into muscle by electroporation. A: Time course study of IL -12 gene expression in serum following a single administration of IL -12 gene to hind limb tibialias muscle with or without electroporation. B: Time course study of IFN -induction following a single administration of IL -12 to muscle with or without electroporation. Significant differences were detected between groups delivered with or without electroporation ( P < .05 ) . C: Level of IL -12 expression in muscle on day 3 following administration of IL -12 gene to hind limb tibialias muscle with or without electroporation. A significant difference was detected between groups delivered with or without electroporation ( P < .05 ) . D: Determination of IL -12 expression in serum after repeated administration of the IL -12 gene to hind limb tibialis muscles, demonstrating the feasibility of multiple application of gene therapy. A significant difference was detected between groups delivered with or without electroporation ( P < .05 ) .
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HANNA, ZHANG, WOODLIS, ET AL: IL-12 GENE THERAPY FOR SQUAMOUS CELL CARCINOMA electroporation. This is 172-fold higher than that when IL -12 was delivered by injection alone, which was 8.4 pg/ mL and only 2.7 pg /mL higher than that of control. The level of IFN -declined after day 6. The level of IFN -in the injection group was the same as or slightly higher than that of naõ Ève mice. These data clearly demonstrate that high levels of IL-12 expression are associated with high levels of induction of IFN -and that IL -12 secreted from muscle is biologically functional.
Effects on establishment of SCC tumors by electroporation delivery of IL -12 gene
To determine if i.m. delivery of IL-12 DNA by electroporation could inhibit SCC tumor establishment, we administered 10 g of IL -12 or empty control DNA plasmid with or without electroporation on the same day as when the SCCVII cells were inoculated. Ten mice for each group were used. The administrations of gene continued once a week for 3 weeks total, using a different hind limb muscle for each administration, proceeding from the left to right tibialis muscle to the left gastrocnemius muscle. Tumor incidence was observed once a week for 3 weeks, and the data were summarized in Table 1 . One week after the inoculation of tumor cell and the first administration of IL-12 gene therapy, all the mice from both control groups and the IL-12 injection group developed tumors, and 3 of 10 mice in the IL -12 electroporated group developed tumors. However, 2 weeks after the tumor cell inoculation and 1 week after the second administration of IL -12 gene or control plasmids to muscle, 4 of 10 mice in the IL -12 gene electroporation group were tumor-free and maintained this tumor-free state until the time of sacrifice 1 month after inoculation of tumor cells. The six mice in the same group that exhibited tumors demonstrated inhibited tumor growth, whereas mice from the other groups showed 100% incidence and aggressive tumor growth ( Table 1) . These data clearly demonstrate that electroporation delivery of IL-12 gene is more effective than that of injection alone.
Effects on established SCC tumor growth by electroporation delivery of IL -12 gene
To determine whether i.m. administration of IL -12 gene by electroporation also inhibits established tumor growth, a separate experiment was performed with five mice in each group. The tumor-bearing mice were generated as described in Materials and Methods. Seven days after tumor inoculation, when tumor volume was about 15 ± 25 mm 3 , IL -12 or control plasmid was delivered to the left hind tibialis muscle, with or without electroporation. A total of three administrations were performed once a week, using a different hind limb muscle for each administration as previously described. Although the tumor was not eradicated, tumor growth in the animals receiving electroporation delivery of IL -12 gene to muscle was significantly reduced compared with that of either control group ( control plasmid with or without electroporation ) or the IL-12 injection group ( Fig 3 ) . These data indicate that electroporation delivery of IL-12 gene is effective in controlling tumor growth.
Cellular change following IL -12 electrogene therapy
To determine the possible cellular mechanism for the increased antitumor efficacy via muscle electroporation delivery of IL -12 gene therapy, we analyzed the NK and T-cell populations in spleen and peripheral blood using flow cytometry. In spleen, both CD4 + and CD8 + T-cell populations decreased by an average of 3 and 2.5 times, respectively, whereas NK cells increased about 3 -to 5 -fold in the group treated with IL -12 muscle electroporation gene therapy compared with the control groups and the IL-12 *Twenty -four days following inoculation of tumor; n = 10; SD.
Figure 2.
Comparison of therapeutic effect of IL -12 gene therapy for the treatment of tumor at distant sites using delivery by muscle electroporation or injection alone. For the tumor growth inhibition study, five mice were used for each treatment or control group. Two control groups were used for all experiments: injection of empty plasmid with or without electroporation. The DNA dose was 10 g for both IL -12 gene or control vector. Because the tumor growth from both control groups was very similar, only the results from the control with electroporation are demonstrated for clarity. The bars in each graph represent the mean + SD. Significant differences in tumor volume between groups with or without electroporation delivery were detected at the endpoint of each experiment ( P < .05 ) . Arrows underneath the abscissa indicated the administration schedule.
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DISCUSSION
Cytokine gene therapy of cancer has been tested using multiple delivery routes, including intradermal, intravenous, intratracheal, and intramuscular injection. 8, 15 Muscle is the most attractive target site for cytokine gene delivery. Large quantities of skeletal muscle are available and accessible for injection. Exogenous plasmids in muscle have been shown to produce expression of transgene proteins for more than 1 year. 9 Finally, anti -DNA antibodies have never been detected in experiments of muscle DNA injection, which allows repeated administrations by i.m. injection. The major drawback with muscle injection of gene expression plasmid is the resulting low level of gene expression. Enhancement of gene expression via chemical formulation showed only limited improvements in the level of gene expression. 16 During the past few years, electroporation delivery of gene to muscle has shown promise in enhancing the gene transfection to muscle fibers and in generating high levels HANNA, ZHANG, WOODLIS, ET AL: IL-12 GENE THERAPY FOR SQUAMOUS CELL CARCINOMA of gene expression. 10 Exposure of skeletal muscle to an optimal electric field has yielded over a 100 -fold increase in gene expression compared to injection alone. 10 However, there have been no reports to determine the therapeutic effect in a tumor model. The data presented here using immunocompetent SCC tumor-bearing mice clearly demonstrate that electroporation delivery of IL -12 gene to muscle is associated with an increased level of functional IL -12 systemic gene expression. The increased systemic level of IL -12 expression resulted in inhibition of tumor establishment (Table 1) when the IL -12 was delivered at the same time as tumor cells were inoculated. The increased level of IL -12 expression also resulted in a reduction of growth of established tumors when IL -12 was delivered after the tumor was well established ( Fig 2 ) .
The profiles of IL -12 gene expression that were observed in this study were similar to those we observed with the reporter gene luciferase in a previous study, in which the level of gene expression peaked at day 7 and declined after a single administration (unpublished data ) . This profile is also similar to that of IL-5 expression delivered by muscle electroporation. 10 Electroporation of IL -12 gene to muscle not only generated high levels of IL -12 expression in serum, but also induced IFNexpression (Fig 3 ) , which is a hallmark of IL -12 immunological response in vivo. 17 Interestingly, although the increase of the levels of IL-12 expression in serum was only 8-fold by muscle electroporation delivery, the level of induction of IFN -was 172 -fold higher than that by injection alone and the peak level reached 1450 pg /mL in the serum at day 6 after electroporation delivery of IL -12 gene into muscle. However, such a level of IFN -expression was still 2 -to 3-fold less than that induced by i.p. injection of IL -12 recombinant protein 1 g /day /mouse for five consecutive days, 19 in which significant tumor regression was observed. Despite that the absolute level of induced IFN -was low by electroporation delivery of IL -12 gene, the duration of IFN -was much longer. A single administration IL -12 DNA plasmid by electroporation yielded a level of more than 1000 pg /mL of IFN -for 9 days, but i.p. delivery of IL-12 protein for 5 days with a dose of 1 g /mouse only led to temporary high levels of IFN -induction, which was almost undetectable 2 days after administration of IL -12 protein was stopped. 19 IFN -induction by IL -12 has been shown to correlate with the expression of interferon inducible protein ( IP) -10, mig, 18 and tumor regression. In another study, IFN -antibodies were shown to diminish the IL -12 therapeutic effect. 20 This may be one of the major mechanisms by which tumor growth was inhibited by electroporation delivery of IL -12 gene.
It has been demonstrated that recombinant IL -12 protein therapy and IL -12 gene therapy enhance NK activity. Administration of rIL -12 protein to normal C57BL / 6 mice augmented NK activity, 20 and injection of IL-12 cDNA to the skin of BALB /c mice induced NK activity comparable to that induced by 100 ng of rIL012 protein in C57BL /6 mice. In our study, electroporation delivery of the IL -12 gene to muscle significantly increased the NK cell and decreased
CD4
+ and CD8 + T-cell populations in spleen (Fig 3A ) . The elimination of CD4 + cells from mice bearing CT-26 colon adenocarcinoma dramatically potentiates antitumor activity of IL-12, and depletion of CD4 + cells has significantly increased the survival of Renca -and CT26 -bearing mice. 12, 21 Taken together, these findings indicate that the decreased CD4 + cells we observed in our study may also contribute to the antitumor activity in our model.
The finding that CD8 + T cells were decreased in the spleen after electroporation IL -12 gene therapy was unexpected, and we hypothesize that this may contribute to the increase in the CD8 + T-cell number in peripheral blood found in our study ( Fig 3B ) . It is possible that the CD8 + T cell increase in blood reflects mobilization of these cytotoxic cells to tumor. We will examine this further in future studies.
CONCLUSION
Electroporation delivery of the IL -12 gene to muscle is a simple and effective method of therapy against SCC in a murine model. Although the mechanism is not yet clear, electroporation delivery of IL -12 gene to muscle clearly enhanced antitumor activity and, when the appropriate gene is chosen, electroporated gene delivery will be an attractive strategy for nonviral gene delivery.
